Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 1, 2004, Pages 95-101

  de la Rosa, Rafael ^a   Ruíz Mateos, Ezequiel ^b   Rubio, Amalia ^c   Abad, María Antonia ^b   Vallejo, Alejandro ^b   Rivero, Laura ^b   Genebat, Miguel ^b   Sánchez Quijano, Armando ^b   Lissen, Eduardo ^b   Leal, Manuel ^b  

^a Hospital San Sebastian   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

Author keywords

PI sparing HAART; Resistance mutations; Simplification therapy; Virological rebound

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; REBOUND; STATISTICAL ANALYSIS; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 9144241044     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh012     Document Type: Article

References (23)

1. Palella, F. J., Delaney, K., Moorman, A. et al. (1998). Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. New England Journal of Medicine 338, 853-60.
2. Kaplan, J. E., Hanson, D., Dworkin, M. S. et al. (2000). Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 30, Suppl. 1, S5-S14.
3. Friedland, G. H. & Williams, A. (1999). Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 13, Suppl. 1, S61-S72.
4. Carr, A., Samaras, K., Thorisdottir, A. et al. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093-9.
5. Sulkowski, M. S., Thomas, D. L. & Chaisson, R. E. (2000). Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Journal of the American Medical Association 283, 74-80.
6. Vigoroux, C., Gharakanian, S., Salhi, Y. et al. (1999). Diabetes, insulin resistance and dyslipidaemias in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes and Metabolism 25, 225-32.
7. Van Leeuwen, R. (2002). The Atlantic study: a randomized, open label trial comparing two PI-sparing antiretroviral strategies versus a standard PI-containing regimen, two year follow-up data. In Program and Abstracts of 14th International AIDS Conference, Barcelona, 2002. Abstract MoPeB3089. International AIDS Society. (http://www.aegis.com/conferences)
8. Podzamczer, D., Ferrer, E., Consiglio, E. et al. (2001). Final 12-month results from the COMBINE study: a randomized trial comparing combivir plus nelfinavir or nevirapine in naive patients. In Program and Abstracts of 1st IAS Conference of HIV Pathogenesis and Treatment, Buenos Aires, 2001. Abstract 7. International AIDS Society. (http://www.aegis.com/conferences)
9. Stazewski, S., Morales-Ramirez, J., Tashima, K. et al. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infected adults. Study 006 team. New England Journal of Medicine 341, 1865-73.
10. Moyle, G. & Baldwin, C. (2000). Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Reader 10, 479-85.
11. Murphy, R. L. (2002). Switch studies: a review. HIV Medicine 3, 146-55.
12. Phillips, A. N., Stazewski, S., Lampe, F. et al. (2002). Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. Journal of Infectious Diseases 186, 1086-91.
13. Paredes, R., Mocroft, A., Kira, O. et al. (2000). Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Archives of Internal Medicine 160, 1123-32.
14. Ruiz, L., Negredo, E., Domingo, P. et al. (2001). Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndromes 27, 229-36.
15. Negredo, E., Cruz, L., Paredes, R. et al. (2002). Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapina or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases 34, 504-10.
16. Raffi, F., Bonnet, B., Ferre, V. et al. (2000). Substitution of a non-nucleoside reverse transcriptase in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clinical Infectious Diseases 31, 1274-8.
17. Martínez-Picado, J., DePasquale, M. P., Kartsonis, N. et al. (2000). Antiretroviral resistance during successful therapy of HIV type 1 infection. Proceedings of the National Academy of Sciences, USA 97, 10948-53.
18. Vanhove, G. F., Schapiro, J. M., Winters, M. A. et al. (1996). Patient compliance and drug failure in protease inhibitor monotherapy. Journal of the American Medical Association 24, 1955-6.
19. Mehta, S., Moore, R. D. & Graham, N. M. H. (1997). Potential factors affecting adherence with HIV therapy. AIDS 11, 1665-70.
20. Trotta, M. P., Ammasari, A., Melzi, S. et al. (2002). Treatment-related factors and highly active antiretroviral therapy adherence. Journal of Acquired Immune Deficiency Syndromes 31, S128-131.
21. Richman, D. D., Havlir, D., Corbeil, J. H. et al. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 68, 1660-6.
22. Vella, S. & Floridia, M. (1998). Saquinavir. Clinical pharmacology and efficacy. Clinical Pharmacokinetics 34, 189-201.
23. Masquelier, B., Neau, D., Chene, G. et al. (2001). Mechanism of virological failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. Journal of Acquired Immune Deficiency Syndromes 28, 309-12.